Vaccination in the Yugoslav National Army: A Significant Risk Factor for Acquiring Chronic Hepatitis B Virus Infection During Army Service in the Former Yugoslavia

Nina Grasselli Kmet¹, *, Mario Poljak², Mojca Rajter¹, Tanja Selić³, Zvonko Baklan⁴, Emil Pal⁵ and Mojca Matičič⁶

¹University Medical Center Ljubljana, Ljubljana, Slovenia
²Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
³Department of Infectious Diseases and Febrile Conditions, General Hospital Celje, Celje, Slovenia
⁴Department of Infectious Diseases and Febrile Illnesses, University Clinical Centre Maribor, Maribor, Slovenia
⁵General Hospital Murska Sobota, Maribor, Slovenia
⁶Medical Faculty, University of Ljubljana, Ljubljana, Slovenia

*Corresponding author: University Medical Center Ljubljana, Ljubljana, Slovenia. Email: dr.ninika@gmail.com

Received 2020 December 07; Accepted 2021 March 03.

Abstract

Background: To prevent the spread of infectious diseases, several state armies implemented obligatory vaccination programs also practiced in the former Yugoslav National Army (YNA). Iatrogenic hepatitis B virus (HBV) transmissions during vaccinations in the armies were well documented, but to the best of our knowledge, no such study has been performed in the former Yugoslavia.

Objectives: In the present study, we determined risk factors for acquiring chronic hepatitis B (CHB) infection in patients in Slovenia. This study focused on the detection of a statistically significant risk factor in males, namely “vaccination in the YNA”.

Methods: One thousand seven hundred and twenty-nine patients from all Slovenian regions who tested positive for HBV surface antigen (HBsAg) at the national referential laboratory for viral hepatitis diagnostics between January 1997 and December 2010 were included retrospectively. Accordingly, demographic, epidemiological, virological, and clinical data were extracted from the medical documentation and were statistically analyzed.

Results: For 1,122 (64.9%) out of 1,729 patients, data regarding risk factors for acquiring HBV infection were available. The risk factor for infection of almost 60% of HBV chronically infected individuals with available data, but to the best of our knowledge, no such study has been performed in the former Yugoslavia.

Conclusions: A significant risk factor for infection in Slovenian men over 46 years of age was identified as “vaccination in the YNA”, which is specific to this geographic region and, to the best of our knowledge, has not been previously described in the peer-reviewed literature.

Keywords: Chronic Hepatitis B Infection, Risk Factors in Males, Vaccination in the Yugoslav National Army

1. Background

It is estimated that 257 million individuals worldwide are chronically infected with the hepatitis B virus (HBV) (1). The average prevalence of HBV infection in Europe is about 2% and in Slovenia is less than 1% (2), and also HBV genotype D prevails in 84.4% of chronically infected Slovenians (3). HBV infection is the major cause of chronic liver disease and associated mortality, remaining high despite effective vaccines and treatments (4, 5). In Europe, the most important modes of transmission in chronically infected individuals are transmission within the family, followed by sexual and parenteral transmission (6). Before routinely adopting safety measures to prevent HBV transmission or in settings where these measures were not strictly used, parenteral transmission and iatrogenic exposure to HBV including vaccinations represented important causes of HBV transmission and infection (7).

To prevent the spread of infectious diseases, several state armies implemented obligatory vaccination programs for both conscripts and professional soldiers, also
practiced in the former Yugoslav National Army (YNA). However, in the past century, iatrogenic HBV transmissions during vaccinations in armies were well documented, but to the best of our knowledge, no such study was performed in the former Yugoslavia (8, 9).

2. Objectives

The present study aimed to define epidemiological, clinical, and virological characteristics of males from Slovenia reporting “vaccination in the YNA” as a risk factor for acquiring chronic hepatitis B (CHB) infection and to examine its importance within the epidemiological situation of CHB in the geographic region of the former Yugoslavia.

3. Methods

3.1. Patients

In a retrospective study, all patients (n = 1,729) from all regions of Slovenia whose blood samples tested positive for HBV surface antigen (HBsAg) at the Laboratory for Molecular Microbiology and Diagnostics of Hepatitis and HIV/AIDS, Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana were included between January 1997 and December 2010. Available epidemiological, virological, and clinical data were reviewed using medical documentation. Among the patients, seven men reported “vaccination in the YNA” as a risk factor for acquiring CHB.

3.2. Microbiological and Molecular Methods

During the studied period, different automated analyzers and commercial tests were used for the detection of HBsAg and HB e antigen (HBeAg). Until the year 2000, routine diagnostics were performed using the enzyme immunoassay test on a Cobas Core analyzer (Roche Diagnostics, Mannheim, Germany). Since the end of the year 2000, the electrochemiluminescence immunoassay tests Cobas HBsAg and Cobas HBeAg (Roche Diagnostics) on an Elecsys 2010 analyzer (Roche Diagnostics) were implemented. HBsAg testing was switched to the ARCHITECT immunoassay analyzer (Abbott, Weisbaden, Germany) in 2006. Since then, HBsAg was routinely tested with the HBsAg qualitative test (Abbott), based on a chemiluminescent magnetic immunoassay technology.

Different assays for detection of HBV DNA viral loads were used as well. Detection of HBV DNA in clinical samples started in 1997 with the Digene HBV DNA test (Digene Corporation, Gaithersburg, Maryland, USA) using Hybrid Capture II technology. In the same year, the PCR-based test with colorimetric determination of amplified products, Amplicor HBV monitor test (Roche Diagnostics, Branchburg, New Jersey, USA), was employed in routine diagnostics. At the beginning of 2004, the test was replaced with the Versant HBV DNA 3.0 (Bayer Diagnostics, Berkeley, California, USA), a branched DNA-based test, and by the commercial real-time PCR test Abbott real time HBV test (Abbott) in 2007. In addition to the mentioned tests, the Cobas TaqMan HBV test (Roche), a real-time PCR test, was used since 2004 as a supplementary method. In statistical analysis, all results were presented in IU/mL (1IU/mL = 5.6 copies/mL = 0.00002 pg/mL, according to the manufacturer's instructions).

3.3. Statistical Methods

The association between patients’ characteristics and risk factors was tested using chi square test or likelihood ratio test, where appropriate. Significance tests were two-sided. P-values of 0.05 or less were considered statistically significant. Statistical analysis was performed using R program 3.1.1 and SPSS 23.0.

The study was approved by the National Medical Ethics Committee (NMEC) of the Republic of Slovenia (consent number 6/04/15).

4. Results

For 1,122 (64.9%) out of 1,729 patients, a most probable self-identified risk factor for acquiring HBV infection was available (Table 1). In almost 60% of HBV chronically infected individuals with available data, the risk factor for infection was unknown. The proportion of known risk factors is presented in Table 1.

There were seven (0.6%) males (mean age ± SD, 53.7 ± 4.50 years) reporting “vaccination in the YNA” as a risk factor for acquiring CHB infection. All investigated males were originally from Slovenia. Among seven cases, six (86.3%) were HBeAg-negative and had viral loads higher than 20,000 IU/mL; also, four (57.1%) cases had alanine aminotransferase levels (ALT) above 0.56 µkat/L. Demographic, epidemiological, clinical, and virological characteristics of males vaccinated in the YNA are summarized in Tables 2 and 3.

Analysis of risk factors for acquiring CHB in terms of age group and gender in included individuals showed “vaccination in the YNA” as a statistically significant risk.
factor for acquiring HBV infection in men over 46 years of age \( (P = 0.006) \) (Table 1).

5. Discussion

The unexpected finding of the present study showed the identification of “vaccination in the YNA” as a risk factor for acquiring HBV infection, which was significantly more common in Slovenian men over 46 years of age. This risk factor seems specific to this geographic region and, to the best of our knowledge, has not been previously described in the peer-reviewed literature.

In order to prevent the spread of infectious diseases, several state armies worldwide implemented obligatory vaccination programs of their recruits. During World War II, a notable epidemic of hepatitis B occurred in the United States (US) Army which was linked to yellow fever vaccine containing HBV contaminated human serum (8). Another hepatitis outbreak in the US Army took place between 1971 and 1973 among US military personnel in Fort Hood, Texas, mainly linked to intravenous drug use (IVDU) (10). Sporadic epidemic of HBV infection linked to vaccinations against smallpox and tetanus, typhus and paratyphus A/B (TABT) have been reported in the UK Royal Air Force as well (9).
Table 3. Demographic, Epidemiological, Clinical, and Virological Characteristics of Males Who Served in the Yugoslav National Army (N = 7) a, b

| Patient | Age (y) | Risk Factor | Jaundice | ALT (µkat/L) | HCV/HIV Co-infection | HBV DNA (IU/mL) | Remarks | Therapy |
|---------|---------|-------------|----------|--------------|----------------------|-----------------|----------|---------|
| 1       | 48      | Vaccination in the Yugoslav National Army, receiving blood/blood products transfusion | Y        | 8.38         | N                    | 437606          | SS (2010) | N       |
| 2       | 59      | Vaccination in the Yugoslav National Army | ND       | 1.85         | N                    | 53578           | HCC      | N       |
| 3       | 54      | Vaccination in the Yugoslav National Army | N        | 2.31         | N                    | 5000000         | N        |
| 4       | 54      | Vaccination in the Yugoslav National Army | ND       | 0.51         | N                    | 207143          | N        |
| 5       | 50      | Vaccination in the Yugoslav National Army | Y        | 0.66         | N                    | 2107429         | N        |
| 6       | 51      | Vaccination in the Yugoslav National Army | N        | 0.39         | N                    | 267             | N        |
| 7       | 60      | Vaccination in the Yugoslav National Army, risky sexual behavior, tattooing/piercing | N        | 0.38         | N                    | 11964286        | N        |

Abbreviations: Y, yes; N, no; ND, no data; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; DNA, deoxyribonucleic acid; ALT, alanine aminotransferase; HBeAg, hepatitis B virus surface antigen; HBsAg, hepatitis B e antigen; IU, international units; HCC, hepatocellular carcinoma; SS, spontaneous seroconversion.

a HBsAg is positive for all the patients.
b HBeAg is negative for all the patients except patient 1.

In the former Yugoslavia, all men older than 18 years of age were required to complete military service in the YNA. In the sixties, all men under 40 years of age serving in the YNA were routinely vaccinated against TAPT (11). According to clinical indications, some recruits also received Calmette-Guérin (BCG) and/or smallpox vaccines (12, 13).

Reports can be found on internet forums written by Slovenian men served in the YNA that describe all recruits in a squad being vaccinated with the same syringe (14).

There are very limited reports on vaccination-related HBV infections in the former Yugoslavia. There was, however, a report from the year 1959 on vaccination-related HBV infection connected with the use of the Salk vaccine among children in Motovun, Croatia (15).

In 1964, Birtašević et al. reported an explosive epidemic of HBV infection among recruits serving in a small garrison of the YNA. Altogether, 12 (15.2%) out of 79 recruits were infected, and all of them were vaccinated against TAPT on the same day, showing symptoms 133 - 170 days later (16). The same syringe was used for all recruits and put in boiling water after each injection; however, the exposure time was most probably too short and insufficient. The needles were changed for each recruit, but further examination determined that the syringes were not washed out completely.

Vukšić et al. published a long report on syringe sterilization practices using cooking methods during TAPT vaccination in the YNA and its potential impact on acquiring "infectious hepatitis" during the fifties and at the beginning of the sixties. Syringes were sterilized using either boiling steam at 180°C or boiling water. They found other reasons for the cause of inoculated hepatitis and concluded that TAPT vaccination was not responsible for any sporadic case or small epidemic of hepatitis B among vaccinated YNA staff (17).

The sub-analysis of chronically infected males in our cohort pointed out interesting virological characteristics. The viral loads were extremely high in a majority of the included males vaccinated in the YNA. Animal studies have shown a correlation between the dose of HBV inoculum, the viral load, and the progression of the disease in adult chimpanzees. Very high and very low dose inoculums were associated with a worse clinical outcome, probably due to immunologic factors (18). A possible cause of high viral loads might also be the increased susceptibility of males to the infection due to the influence of androgens, also being supported by the results of a study on transgenic laboratory mice (19). For a susceptible person, the risk of a single needle stick or cut exposure to HBV-infected blood in health-care incidents ranges from 1 to 40% and depends on the HBeAg status of the source individual. Infected individuals with HBeAg positive have higher viral loads and are more likely to transmit HBV than those with HBeAg negative. Risk of transmission in case of HBeAg-positive infection ranges between 22 and 40%, and in case of HBeAg-negative infection it is between 1 and 6% (20). According to a report from 1973, a 6.44% prevalence of HBsAg among 2,500 willing blood donors serving the YNA was found; however, data on the presence of HBeAg are not available (21).

A majority of males in our cohort reporting "vaccina-
tion in the YNA" as a risk factor for acquiring HBV infection were HBsAg-negative, being in accordance with known epidemiological data. HBsAg-negative HBV infection prevails in the Mediterranean region (22) and its prevalence in Slovenia has been estimated at 85.5% (23).

Although all males who reported "vaccination in the YNA" as a risk factor for acquiring HBV infection met Slovenian (24) and European Association for the Study of the Liver (EASL) treatment criteria (25), only one received hepatitis B treatment. The reasons for this finding are heterogeneous: (1) four of the cases were not regularly followed-up; (2) one was spontaneously seroconverted; and (3) one was diagnosed with an advanced stage of hepatocellular carcinoma (HCC).

This study has several limitations. The risk factor of "vaccination in the YNA" was added to the study protocol after the retrospective revision of patients’ charts. Since in the former Yugoslavia all men above 18 years of age were required to serve in the YNA, more males of the study population in an appropriate age might have got HBV infection as a result of vaccination in the YNA but they did not recall it as a possible risk factor. Another bias is in lack of some clinical and/or virological data for some of the included individuals. In our study, only the Slovenian population was included. Data could be more relevant if HBsAg-positive males from all republics of the former Yugoslavia were included.

The strength of the study lies in identifying "vaccination in the YNA" as a significant risk factor for HBV infection in males over 46 years of age, which is specific to this geographic region. Since most men over 46 years of age currently living in the countries of the former Yugoslavia served in the YNA, HBV testing and counseling should be routinely offered to this population across the geographic region of the former Yugoslavia.

Footnotes

Authors’ Contribution: Study concept and design, N.G.K., M.P., and M.M.; Acquisition of data, N.G.K., M.P., M.R., T.S.K., Z.B., E.P., and M.M.; Analysis and interpretation of data, N.G.K.; Drafting of the manuscript, N.G.K.; Critical revision of the manuscript for important intellectual content, N.G.K., M.P., and M.M.; Statistical analysis, N.G.K.; Administrative, technical, and material support, N.G.K.; Study supervision, N.G.K., M.P., and M.M.

Conflict of Interests: Authors declare no conflict of interest.

Ethical Approval: The study was approved by the National Medical Ethics Committee (NMEC) of the Republic of Slovenia (consent number 6/04/15).

Funding/Support: There is no funding/support.

References

1. World Health Organization. Global hepatitis report. Geneva, Switzerland: World Health Organization; 2017.
2. Ghalayini H, Veldhuizen IK, Wessling L, Lim TA, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: A systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13:381. doi: 10.1186/1471-2334-13-381. [PubMed: 23597411]. [PubMed Central: PMC376892].
3. Kmet Lunacek N, Poljak M, Meglic-Volkar J, Rajter M, Prahl J, Lesnicar G, et al. Epidemiological, virological and clinical characteristics of hepatitis B virus genotypes in chronically infected persons in Slovenia. Hepat Mon. 2017;17(3). e43838. doi: 10.5812/hepatmon.43838.
4. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128. doi: 10.1016/S0140-6736(12)6728-0. [PubMed: 23245604].
5. Locarnini S, Hatzakis A, Chen DS, Lok A. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol. 2015;62(1 Suppl):S76-86. doi: 10.1016/j.jhep.2015.01.018. [PubMed: 25920093].
6. European Centre for Disease Prevention and Control. Hepatitis B. Stockholm: ECDC; 2018.
7. Dienstag JL, Delemos AS. Viral hepatitis. In: Bennett J, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8th ed. Amsterdam: Elsevier Health Sciences; 2014.
8. Sawyer WA, Meyer KP, Eaton MD, Bauer JH, Putnam P, Schwentker FF. Jaundice in army personnel in the Western Region of the United States and its relation to vaccination against yellow fever. Am J Epidemiol. 1944;39(5):337-430. doi: 10.1093/oxfordjournals.aje.a10899l.
9. Zuckerman AJ. Epidemiology of acute hepatitis in the royal air force. Br J Prev Soc Med. 1964;18:183-8. doi: 10.1136/jch.18.1.183. [PubMed: 14216078]. [PubMed Central: PMC358466].
10. Allen AM, Irwin GR, Karwacki JJ, Warren DC, Levine RS. Epidemic hepatitis B: A sustained outbreak in a large military population. Am J Epidemiol. 1975;102(6):545-52. doi: 10.1093/oxfordjournals.aje.a112992. [PubMed: 1202956].
11. Arsic B. [Vaccination against typhoid, paratyphoid and tetanus in the Yugoslav National Army]. Vojnosanit Pregl. 1967;24(2):94-9. Serbian. [PubMed: 604486].
12. Todorovic B, Pavlovic M, Todorovic-Lero Z, Djokic M, Draganic B. [BCG vaccination and tuberculosis in soldiers of the YNA (Yugoslavian National Army)]. Plone Bolesti Tuberk. 1974;26(Suppl 2):197-7. Croatian. [PubMed: 44452].
13. Bratasevic B, Aric B, Miletic M. [Should the method of smallpox vaccination be changed in the YNA (Yugoslavian National Army)?]. Vojnosanit Pregl. 1975;32(3):308-11. Serbian. [PubMed: 1846248].
14. Forum Over Net. Cephenje monash v tsau JLA. Forum Over Net; 2021; [cited 8th Nov 2018]. Slovenian. Available from: http://med.over.net/forum/5/read.php?151,5833191.
15. Isgum M, Tumir V, Poljak B. [Inoculation or epidemic hepatitis. (Analysis of an epidemic of hepatitis in the commune of motovun in 1959)]. Vojnosanit Pregl. 1964;21:350-3. Serbian. [PubMed: 14260950].
16. Birtasevic B, Bicakcic H, Vuksic L. [Explosive epidemic of inoculation hepatitis]. Vojnosanit Pregl. 1964;21:322-5. Serbian. [PubMed: 14260417].
17. Vuksic L, Jovanovic T, Nikolic B. [Sterilization of syringes by boiling for tabt vaccination in the Yugoslavian Army and its influence on infectious hepatitis]. Vojnosanit Pregl. 1964;21:344-9. Serbian. [PubMed: 14260420].
18. Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, Purcell RH, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol. 2009;83(19):9652-62. doi: 10.1128/JVI.00867-09. [PubMed: 19625407]. [PubMed Central: PMC2748002].
19. Tian Y, Kuo CF, Chen WL, Ou JH. Enhancement of hepatitis B virus replication by androgen and its receptor in mice. J Virol. 2012;86(4):1904-10. doi: 10.1128/JVI.00707-11. [PubMed: 22156518]. [PubMed Central: PMC3302417].
20. Centers for Disease Control and Prevention. Guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. USA: Centers for Disease Control and Prevention; 2001.
21. Drobnajakovic A, Radovic M, Birtasevic B, Stankovic D, Milutinovic D, Parabucki S, et al. [Occurrence of Australia antigen in blood donors-personnel of the YNA (Yugoslavian National Army)]. Vojnosanit Pregl. 1973;30(1):20-3. Serbian. [PubMed: 4632287].
22. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2001;34(4 Pt 1):677-24. doi: 10.1053/jhep.2001.27834. [PubMed: 11584355].
23. Kmet Lunaček N, Matičič M, Markočič P, Lunar M, Meglič-Volkar J, Rajter M, et al. Changes in demographic and virological characteristics of patients with chronic hepatitis B virus infection in Slovenia between 1997 and 2010. Reviews in Antiviral Therapy and Infectious Diseases. 2017;9:6-7.
24. Matičič M, Poljak M. [Slovene national guidelines for the prevention of hepatitis B reactivation in patients undergoing immunosuppressive therapy]. Zdrav-Vestn. 2007;79(9):599-608. Serbian.
25. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. doi: 10.1016/j.jhep.2017.03.021. [PubMed: 28427875].